abstract：Importance:The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and s...

journal_title：JAMA oncology

authors： Slovin S,Clark W,Carles J,Krivoshik A,Park JW,Wang F,George D

更新日期：2018-05-01 00:00:00

abstract：Importance:Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective:To d...

journal_title：JAMA oncology

authors： Mehralivand S,Shih JH,Rais-Bahrami S,Oto A,Bednarova S,Nix JW,Thomas JV,Gordetsky JB,Gaur S,Harmon SA,Siddiqui MM,Merino MJ,Parnes HL,Wood BJ,Pinto PA,Choyke PL,Turkbey B

更新日期：2018-05-01 00:00:00

abstract：Importance:The evidence for concurrent chemoradiotherapy (CT-RT) in International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix is not robust. This study reports the final results of a randomized clinical trial of concurrent cisplatin-based CT-RT and radiotherap...

journal_title：JAMA oncology

authors： Shrivastava S,Mahantshetty U,Engineer R,Chopra S,Hawaldar R,Hande V,Kerkar RA,Maheshwari A,Shylasree TS,Ghosh J,Bajpai J,Gurram L,Gulia S,Gupta S,Gynecologic Disease Management Group.

更新日期：2018-04-01 00:00:00

abstract：Importance:Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). Objective:To examine the association of TTFields therapy with progression-free ...

journal_title：JAMA oncology

authors： Taphoorn MJB,Dirven L,Kanner AA,Lavy-Shahaf G,Weinberg U,Taillibert S,Toms SA,Honnorat J,Chen TC,Sroubek J,David C,Idbaih A,Easaw JC,Kim CY,Bruna J,Hottinger AF,Kew Y,Roth P,Desai R,Villano JL,Kirson ED,Ram Z,

更新日期：2018-04-01 00:00:00

abstract：Importance:Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may ...

journal_title：JAMA oncology

authors： Seligmann JF,Hatch AJ,Richman SD,Elliott F,Jacobs B,Brown S,Hurwitz H,Barrett JH,Quirke P,Nixon AB,Seymour MT

更新日期：2018-04-01 00:00:00

abstract：Importance:The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors. Objective:To perform a validation study of the AJCC eighth edition prognostic stage in a single-institut...

journal_title：JAMA oncology

authors： Weiss A,Chavez-MacGregor M,Lichtensztajn DY,Yi M,Tadros A,Hortobagyi GN,Giordano SH,Hunt KK,Mittendorf EA

更新日期：2018-02-01 00:00:00

abstract：Importance:Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differenc...

journal_title：JAMA oncology

authors： Smeltzer MP,Faris NR,Ray MA,Osarogiagbon RU

更新日期：2018-01-01 00:00:00

abstract：Importance:Why some triple-negative breast cancers (TNBCs) have high and others have low immune cell infiltration is unknown. Understanding how immune surveillance shapes the cancer genome could help in the selection of patients and the development of more effective immunotherapy strategies. Objective:To examine the a...

journal_title：JAMA oncology

authors： Karn T,Jiang T,Hatzis C,Sänger N,El-Balat A,Rody A,Holtrich U,Becker S,Bianchini G,Pusztai L

更新日期：2017-12-01 00:00:00

abstract：Importance:Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. Objective:To assess the survival impact of SPMs in...

journal_title：JAMA oncology

authors： Keegan THM,Bleyer A,Rosenberg AS,Li Q,Goldfarb M

更新日期：2017-11-01 00:00:00

abstract：Importance:The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. Objective:To evaluate the benefit of cetuximab added to concurrent chemoradiation therapy for patients undergoing nonoperative treat...

journal_title：JAMA oncology

authors： Suntharalingam M,Winter K,Ilson D,Dicker AP,Kachnic L,Konski A,Chakravarthy AB,Anker CJ,Thakrar H,Horiba N,Dubey A,Greenberger JS,Raben A,Giguere J,Roof K,Videtic G,Pollock J,Safran H,Crane CH

更新日期：2017-11-01 00:00:00

abstract：Importance:Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective:To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, Setting, and Participants:This single-center, rando...

journal_title：JAMA oncology

authors： Yap YS,Kwok LL,Syn N,Chay WY,Chia JWK,Tham CK,Wong NS,Lo SK,Dent RA,Tan S,Mok ZY,Koh KX,Toh HC,Koo WH,Loh M,Ng RCH,Choo SP,Soong RCT

更新日期：2017-11-01 00:00:00

abstract：Importance:Evidence for application of stereotactic and other conformal radiotherapy techniques in treating brain tumors is largely based on data derived from dosimetric, retrospective, or small prospective studies. Therefore, we conducted a randomized clinical trial of stereotactic conformal radiotherapy (SCRT) compar...

journal_title：JAMA oncology

authors： Jalali R,Gupta T,Goda JS,Goswami S,Shah N,Dutta D,Krishna U,Deodhar J,Menon P,Kannan S,Sarin R

更新日期：2017-10-01 00:00:00

abstract：Importance:Novel intermediate end points may be useful to detect signals of early activity and prioritize new therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC). Objective:To explore milestone rate, a proposed intermediate end point for immunotherapy...

journal_title：JAMA oncology

authors： Blumenthal GM,Zhang L,Zhang H,Kazandjian D,Khozin S,Tang S,Goldberg K,Sridhara R,Keegan P,Pazdur R

更新日期：2017-08-10 00:00:00

abstract：Importance:Multiple myeloma (MM) is the second most common hematological malignant abnormality. The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has greatly improved the overall survival of patients with MM. Prevention and treatment of cardiovascular and thrombotic issues associated wi...

journal_title：JAMA oncology

authors： Li W,Garcia D,Cornell RF,Gailani D,Laubach J,Maglio ME,Richardson PG,Moslehi J

更新日期：2017-07-01 00:00:00

abstract：Importance:Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. Objective:To investigate temporal trends and...

journal_title：JAMA oncology

authors： Daly B,Olopade OI,Hou N,Yao K,Winchester DJ,Huo D

更新日期：2017-07-01 00:00:00

abstract：Importance:Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast ...

journal_title：JAMA oncology

authors： Joensuu H,Kellokumpu-Lehtinen PL,Huovinen R,Jukkola-Vuorinen A,Tanner M,Kokko R,Ahlgren J,Auvinen P,Lahdenperä O,Kosonen S,Villman K,Nyandoto P,Nilsson G,Poikonen-Saksela P,Kataja V,Junnila J,Bono P,Lindman H

更新日期：2017-06-01 00:00:00

abstract：Importance:Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HP...

journal_title：JAMA oncology

authors： Han JJ,Beltran TH,Song JW,Klaric J,Choi YS

更新日期：2017-06-01 00:00:00

abstract：Importance:Lay navigators in the Patient Care Connect Program support patients with cancer from diagnosis through survivorship to end of life. They empower patients to engage in their health care and navigate them through the increasingly complex health care system. Navigation programs can improve access to care, enhan...

journal_title：JAMA oncology

authors： Rocque GB,Pisu M,Jackson BE,Kvale EA,Demark-Wahnefried W,Martin MY,Meneses K,Li Y,Taylor RA,Acemgil A,Williams CP,Lisovicz N,Fouad M,Kenzik KM,Partridge EE,Patient Care Connect Group.

更新日期：2017-06-01 00:00:00

abstract：Importance:Hereditary cancer syndromes infer high cancer risks and require intensive cancer surveillance, yet the prevalence and spectrum of these conditions among unselected patients with early-onset colorectal cancer (CRC) is largely undetermined. Objective:To determine the frequency and spectrum of cancer susceptib...

journal_title：JAMA oncology

authors： Pearlman R,Frankel WL,Swanson B,Zhao W,Yilmaz A,Miller K,Bacher J,Bigley C,Nelsen L,Goodfellow PJ,Goldberg RM,Paskett E,Shields PG,Freudenheim JL,Stanich PP,Lattimer I,Arnold M,Liyanarachchi S,Kalady M,Heald B,Gre

更新日期：2017-04-01 00:00:00

abstract：Importance:Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care. Objective:To examine the association of outco...

journal_title：JAMA oncology

authors： Wang CJ,Cheng SH,Wu JY,Lin YP,Kao WH,Lin CL,Chen YJ,Tsai SL,Kao FY,Huang AT

更新日期：2017-03-01 00:00:00

abstract：Importance:Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. Objective:To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI...

journal_title：JAMA oncology

authors： Melisko ME,Goldman ME,Hwang J,De Luca A,Fang S,Esserman LJ,Chien AJ,Park JW,Rugo HS

更新日期：2017-03-01 00:00:00

abstract：Importance:There are long-standing interests in the potential benefits of vitamin D for preventing breast cancer recurrence and mortality, yet data from prospective cohort studies are limited. Objective:To investigate a serum biomarker of vitamin D status, 25-hydroxyvitamin D (25OHD) measured at the time of breast can...

journal_title：JAMA oncology

authors： Yao S,Kwan ML,Ergas IJ,Roh JM,Cheng TD,Hong CC,McCann SE,Tang L,Davis W,Liu S,Quesenberry CP Jr,Lee MM,Ambrosone CB,Kushi LH

更新日期：2017-03-01 00:00:00

abstract：Importance:Within 10 years after breast cancer diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC). Randomized trials have found that therapy including tamoxifen citrate and aromatase inhibitors (AIs) reduces CBC risk. But little is known about the magnitude and duration of protective associatio...

journal_title：JAMA oncology

authors： Gierach GL,Curtis RE,Pfeiffer RM,Mullooly M,Ntowe EA,Hoover RN,Nyante SJ,Feigelson HS,Glass AG,Berrington de Gonzalez A

更新日期：2017-02-09 00:00:00

abstract：Importance:Primary tumor location is emerging as an important prognostic factor owing to distinct biological features. However, the side of origin of colon cancer (CC) still does not represent a prognostic parameter when deciding for adjuvant or palliative chemotherapy. Objective:To determine the prognostic role of le...

journal_title：JAMA oncology

authors： Petrelli F,Tomasello G,Borgonovo K,Ghidini M,Turati L,Dallera P,Passalacqua R,Sgroi G,Barni S

更新日期：2017-02-01 00:00:00

abstract：Importance:Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. Objective:To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fl...

journal_title：JAMA oncology

authors： Tejpar S,Stintzing S,Ciardiello F,Tabernero J,Van Cutsem E,Beier F,Esser R,Lenz HJ,Heinemann V

更新日期：2017-02-01 00:00:00

abstract：Importance:Programmed cell death 1 (PD-1) inhibitor-related pneumonitis is a rare but clinically serious and potentially life-threatening adverse event. Little is known about its incidence across different tumor types and treatment regimens. Objective:To compare the incidence of PD-1 inhibitor-related pneumonitis amon...

journal_title：JAMA oncology

authors： Nishino M,Giobbie-Hurder A,Hatabu H,Ramaiya NH,Hodi FS

更新日期：2016-12-01 00:00:00

abstract：Importance:Financial conflicts of interest (FCOIs) among authors of clinical practice guidelines have the potential to influence treatment recommendations. Objective:To quantify FCOIs with industry among authors of the National Comprehensive Cancer Network (NCCN) guidelines. Design, Setting, and Participants:We asses...

journal_title：JAMA oncology

authors： Mitchell AP,Basch EM,Dusetzina SB

更新日期：2016-12-01 00:00:00

abstract：Importance:Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have achieved success in treating a number of malignancies. However, only a subset of patients responds to these therapies, and optimization of patient sele...

journal_title：JAMA oncology

authors： Dijkstra KK,Voabil P,Schumacher TN,Voest EE

更新日期：2016-11-01 00:00:00

abstract：Importance:While adjuvant hormonal therapy (HT) reduces mortality for women with nonmetastatic breast cancer, nonadherence to HT is common. Objective:We investigated the association between patterns of prior nonadherence to medications for chronic conditions with HT nonadherence. Design, Setting, and Participants:For...

journal_title：JAMA oncology

authors： Neugut AI,Zhong X,Wright JD,Accordino M,Yang J,Hershman DL

更新日期：2016-10-01 00:00:00

abstract：Importance:The role of cytoreductive nephrectomy in patients with metastatic renal cancer in the era of targeted therapy is uncertain. Objective:To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metastatic clear cell renal cancer....

journal_title：JAMA oncology

authors： Powles T,Sarwar N,Stockdale A,Sarker SJ,Boleti E,Protheroe A,Jones R,Chowdhury S,Peters J,Oades G,O'Brien T,Sullivan M,Aitchison M,Beltran L,Worth D,Smith K,Michel C,Trevisan G,Harvey-Jones E,Wimalasingham A,Sahde

更新日期：2016-10-01 00:00:00

abstract：Importance:Esophageal adenocarcinoma and its precursor lesion Barrett esophagus have seen a dramatic increase in incidence over the past 4 decades yet marked genetic heterogeneity of this disease has precluded advances in understanding its pathogenesis and improving treatment. Objective:To identify novel disease susce...

journal_title：JAMA oncology

authors： Fecteau RE,Kong J,Kresak A,Brock W,Song Y,Fujioka H,Elston R,Willis JE,Lynch JP,Markowitz SD,Guda K,Chak A

更新日期：2016-10-01 00:00:00

abstract：IMPORTANCE:Time to events, or survival end points, are common end points in randomized clinical trials. They are usually analyzed under the assumption of proportional hazards, and the treatment effect is reported as a hazard ratio, which is neither an intuitive measure nor a meaningful one if the assumption of proporti...

journal_title：JAMA oncology

authors： Péron J,Roy P,Ozenne B,Roche L,Buyse M

更新日期：2016-07-01 00:00:00

abstract：IMPORTANCE:Positive phase 3 cancer clinical trials are widely hailed, while trials with negative results are often interpreted as scientific failures. We hypothesized that these interpretations would be reflected in the scientific literature. OBJECTIVE:To compare the scientific impact of positive vs negative phase 3 c...

journal_title：JAMA oncology

authors： Unger JM,Barlow WE,Ramsey SD,LeBlanc M,Blanke CD,Hershman DL

更新日期：2016-07-01 00:00:00

abstract：IMPORTANCE:BRCA testing is recommended for young women diagnosed as having breast cancer, but little is known about decisions surrounding testing and how results may influence treatment decisions in young patients. OBJECTIVES:To describe the use of BRCA testing and to evaluate how concerns about genetic risk and use o...

journal_title：JAMA oncology

authors： Rosenberg SM,Ruddy KJ,Tamimi RM,Gelber S,Schapira L,Come S,Borges VF,Larsen B,Garber JE,Partridge AH

更新日期：2016-06-01 00:00:00

abstract：IMPORTANCE:Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized. OBJECTIVE:To identify circumstances in which a high ORR is associated with regulatory approval, and t...

journal_title：JAMA oncology

authors： Oxnard GR,Wilcox KH,Gonen M,Polotsky M,Hirsch BR,Schwartz LH

更新日期：2016-06-01 00:00:00

abstract：Importance:RAS wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy in aCRC, so may repres...

journal_title：JAMA oncology

authors： Seligmann JF,Elliott F,Richman SD,Jacobs B,Hemmings G,Brown S,Barrett JH,Tejpar S,Quirke P,Seymour MT

更新日期：2016-05-01 00:00:00

abstract：IMPORTANCE:Time to surgery (TTS) is of concern to patients and clinicians, but controversy surrounds its effect on breast cancer survival. There remains little national data evaluating the association. OBJECTIVE:To investigate the relationship between the time from diagnosis to breast cancer surgery and survival, usin...

journal_title：JAMA oncology

authors： Bleicher RJ,Ruth K,Sigurdson ER,Beck JR,Ross E,Wong YN,Patel SA,Boraas M,Chang EI,Topham NS,Egleston BL

更新日期：2016-03-01 00:00:00

abstract：IMPORTANCE:A recent randomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a lower survival rate in the high-dose radiation therapy (RT) arm (74 Gy) than in the low-dose arm (60 Gy) with concurrent chemotherapy. OBJE...

journal_title：JAMA oncology

authors： Movsas B,Hu C,Sloan J,Bradley J,Komaki R,Masters G,Kavadi V,Narayan S,Michalski J,Johnson DW,Koprowski C,Curran WJ Jr,Garces YI,Gaur R,Wynn RB,Schallenkamp J,Gelblum DY,MacRae RM,Paulus R,Choy H

更新日期：2016-03-01 00:00:00

abstract：IMPORTANCE:BRCA genetic testing has substantial public health impact, yet little is known of the real-world experiences of the more than 100 000 Americans undergoing testing annually. OBJECTIVE:To identify factors associated with use of BRCA testing, assess whether delivery of genetic counseling and testing services a...

journal_title：JAMA oncology

authors： Armstrong J,Toscano M,Kotchko N,Friedman S,Schwartz MD,Virgo KS,Lynch K,Andrews JE,Aguado Loi CX,Bauer JE,Casares C,Bourquardez Clark E,Kondoff MR,Molina AD,Abdollahian M,Walker G,Sutphen R

更新日期：2015-12-01 00:00:00

abstract：IMPORTANCE:Contrary to practice guidelines, breast magnetic resonance imaging (MRI) is commonly used in the preoperative evaluation of women with breast cancer. While existing literature has found little benefit to MRI in most patients, potential downstream consequences associated with breast MRI are not well described...

journal_title：JAMA oncology

authors： Arnaout A,Catley C,Booth CM,McInnes M,Graham I,Kumar V,Simos D,Van Walraven C,Clemons M

更新日期：2015-12-01 00:00:00